Patient health utility, work productivity, and lifestyle impairment in chronic hepatitis C patients in France

Clinics and Research in Hepatology and Gastroenterology

Volumn 39, Issue 3, 2015, Pages 307-314

  Samp, Jennifer C ^a   Perry, Richard ^a   Piercy, James ^a   Wood, Robert ^a   Baran, Robert W ^a  

^a ABBVIE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABSENTEEISM; ADULT; AGE; ARTICLE; CHRONIC HEPATITIS C; DAILY LIFE ACTIVITY; DEMOGRAPHY; DISEASE COURSE; DISEASE SEVERITY; EQ 5D INDEX; FEMALE; FRANCE; GENERAL HEALTH STATUS ASSESSMENT; HEALTH CARE UTILIZATION; HEALTH STATUS; HEPATITIS C VIRUS SPECIFIC WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRODUCTIVITY; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ANALOG SCALE; CROSS-SECTIONAL STUDY; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; WORK;

CROSS-SECTIONAL STUDIES; EFFICIENCY; FEMALE; FRANCE; HEALTH STATUS; HEPATITIS C, CHRONIC; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; WORK;

EID: 84930872347     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2014.10.013     Document Type: Article

References (27)

1. World Health Organization (WHO) Hepatitis C fact sheet No. 164. Revised 2013 2013, Available at http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed November 29, 2013.
2. Hatzakis A., Wait S., Bruix J., et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hep 2011, 18(Suppl. 1):1-16.
3. Meffre C., Strat Le L., Delarocque-Astagneau, et al. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. J Med Virol 2010, 82:546-555.
4. Muhlberger N., Schwarzer R., Lettmeier B., et al. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009, 9:34.
5. Shepherd J., Jones J., Hartwell D., et al. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2007, 11:1-205.
6. Seeff L.B. Natural history of chronic hepatitis C. Hepatology 2002, 36:S35-S46.
7. Biggins S.W., Bambha K.M., Terrault N.A., et al. Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma. Liver Transpl 2012, 18:1471-1478.
8. Deuffic-Burban S., Deltenre P., Buti M., Stroffolini T., Parkes J., Muhlberger N., et al. Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology 2012, 143:974-985.
9. Chong C.A., Gulamhussein A., Heathcote E.J., Lilly L., Sherman M., Naglie G., et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003, 98:630-638.
10. Rowan P.J., Al-Jurdi R., Tavakoli-Tabasi S., Kunik M.E., Satrom S.L., EL-Serag H.B. Physical and psychosocial contributors to quality of life in veterans with hepatitis C not on antiviral therapy. J Clin Gastroenterol 2005, 39:731-736.
11. Younossi Z.M., Boparai N., Price L.L., Kiwi M.L., McCormick M., Guyatt G. Health-related quality of life in chronic liver disease: the impact of type and severity of disease. Am J Gastroenterol 2001, 96:2199-2205.
12. Gutteling J.J., de Man R.A., van der Plas S.M., et al. Determinants of quality of life in chronic liver patients. Aliment Pharmacol Ther 2006, 23:1629-1635.
13. Hsu P.C., Frederico C.A., Krajden M., et al. Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection. J Gastroentero Hepatol 2012, 27:149-157.
14. Kleinman L., Mannix S., Yuan Y., et al. Review of patient-reported outcome measures in chronic hepatitis C. Health Qual Life Outcomes 2012, 10:92.
15. McHutchison J.G., et al. The effects of interferon alpha-2b in combination with ribavirin on health-related quality of life and work productivity. J Hepatol 2001, 34:140-147.
16. Spiegel B.M., Younossi Z.M., Hays R.D., et al. Impact of hepatitis C on health-related quality of life: a systematic review and quantitative assessment. Hepatology 2005, 41:790-800.
17. Vera-Llonch M., Martin M., Aggarwal J., Donepudi M., Bayliss M., Goss T., et al. Health-related quality of life in genotype 1 treatment-naive chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study. Aliment Pharmacol Ther 2013, 38:124-133.
18. Myers R.P., Cooper C., Sherman M., et al. Outcomes of chronic hepatitis C therapy in patients treated in community versus academic centres in Canada: final results of APPROACH (a prospective study of peginterferon alfa-2a and ribavirin at academic and community centres in Canada). Can J Gastroenterol 2011, 25(9):503-510.
19. El Khoury A.C., Wallace C., Klimack W.K., et al. Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas. J Med Econ 2012, 15(5):887-896.
20. DaCosta DiBonaventura M., Wagner J.S., Yuan Y., L'Italien G., Langley P., Ray K.W. The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities. J Med Econ 2011, 14:253-261.
21. Vietri J., Prajapati G., El Khoury A.C. The burden of hepatitis C in Europe from the patients' perspective: a survey in 5 countries. BMC Gastroenterol 2013, 13:16.
22. The Euroqol Group EQ-5D-5L User Guide 2013, Available at http://www.euroqol.org. Accessed December 4, 2013.
23. Björnsson E., Verbaan H., Oksanen A., Frydén A., Johansson J., Friberg S., et al. Health-related quality of life in patients with different stages of liver disease induced by hepatitis C. Scand J Gastroenterol 2009, 44(7):878-887.
24. Reilly M.C., Zbrozek A.S., Dukes E.M. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993, 4:353-365.
25. Scott J., Gilles L., Fu M., et al. Adding simeprevir to pegylated interferon-ribavirin for HCV shortens time with patient-reported symptoms and impairment in quality of life: results from the simeprevir phase III QUEST 1, QUEST 2, and PROMISE studies 2013, 1116. AASLD Annual Meeting Abstracts.
26. Backx M., Lewszuk A., White J.R., et al. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy. J Viral Hep 2014, 21:208-215.
27. Manne V., Sassi K., Allen R., et al. Hepatitis C and work impairment: a review of current literature. J Clin Gastroenterol 2014, 48(7):595-599.